What’s Ahead for Pulse Biosciences Inc (PLSE) After Today’s Big Decline?

September 13, 2017 - By Linda Rogers

The stock of Pulse Biosciences Inc (NASDAQ:PLSE) is a huge mover today! The stock decreased 25.60% or $3.53 during the last trading session, reaching $10.26. About 1.63 million shares traded or 727.86% up from the average. Pulse Biosciences Inc (NASDAQ:PLSE) has 0.00% since September 13, 2016 and is . It has underperformed by 16.70% the S&P500.
The move comes after 6 months negative chart setup for the $147.07 million company. It was reported on Sep, 13 by Barchart.com. We have $9.85 PT which if reached, will make NASDAQ:PLSE worth $5.88 million less.

More notable recent Pulse Biosciences Inc (NASDAQ:PLSE) news were published by: Prnewswire.com which released: “Kerrisdale Capital Issues Negative Report on Pulse Biosciences, Inc. and …” on May 09, 2017, also Businesswire.com with their article: “Pulse Biosciences Submits 510(k) Application to FDA for PulseTxâ„¢ System” published on March 14, 2017, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on September 11, 2017. More interesting news about Pulse Biosciences Inc (NASDAQ:PLSE) were released by: Seekingalpha.com and their article: “Pulse Biosciences, Inc.: High-Voltage Hype Set To Short-Circuit” published on May 09, 2017 as well as Businesswire.com‘s news article titled: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Pulse …” with publication date: September 11, 2017.

Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device firm using a platform technology called Nano-Pulse Electro-Signaling . The company has market cap of $147.07 million. NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. It currently has negative earnings. NPES provides treatment in a range of dermatology and aesthetic applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.